Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Circassia Pharmaceuticals ( (GB:NIOX) ) has shared an update.
NIOX Group plc, a company listed on AIM, has issued 144,844 new ordinary shares to Ian Johnson, the Non-Executive Chairman, under its Deferred Share Bonus Plan. This issuance relates to the annual bonus for the 2023 financial year, initially granted when Johnson was Executive Chairman. The deferral period for these shares was waived upon his transition to Non-Executive Chairman, allowing for the allotment of the shares. This transaction increases the total issued share capital of the company to 417,751,925 ordinary shares, impacting the voting rights and shareholding structure.
The most recent analyst rating on (GB:NIOX) stock is a Buy with a £77.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.
Spark’s Take on GB:NIOX Stock
According to Spark, TipRanks’ AI Analyst, GB:NIOX is a Neutral.
Circassia Pharmaceuticals (GB:NIOX) shows strength in financial performance with stable cash flow and revenue growth, which are major contributors to its score. The high corporate events score reflects strategic initiatives and positive sales momentum. However, the valuation presents concerns due to a high P/E ratio and an unusual dividend yield. Technical analysis suggests caution due to mixed indicators.
To see Spark’s full report on GB:NIOX stock, click here.
More about Circassia Pharmaceuticals
Average Trading Volume: 1,444,202
Technical Sentiment Signal: Buy
Current Market Cap: £270.5M
See more insights into NIOX stock on TipRanks’ Stock Analysis page.